Summary:
Tinnitus UK has named Lenire by Neuromod as the highest-rated tinnitus treatment for safety and effectiveness, recognizing its strong clinical evidence.

Key Takeaways:

  • Lenire’s bimodal neuromodulation therapy combines sound and tongue stimulation to provide long-lasting tinnitus relief.
  • The updated Tinnitus UK rating reflects years of research, including three large-scale clinical trials with over 600 participants.
  • Lenire is now available through hearing care professionals across the UK, Europe, and the US, alongside established treatments like CBT and hearing aids.

Tinnitus UK, a tinnitus advocacy body, announced that according to the charity’s treatment rating review, Lenire by Neuromod is now the highest rated available tinnitus treatment option for safety and effectiveness.

According to the company, Lenire is now considered to be very safe, with a level of efficacy currently matched only by professional cognitive behavioral therapy (CBT) and hearing aids. 

“Neuromod welcomes Tinnitus UK’s decision to recognize Lenire, and bimodal neuromodulation, as a safe and effective standard of care for tinnitus treatment,” says Neuromod founding CEO, Dr Ross O’Neill. “Millions of people in the UK and across Europe rely on Tinnitus UK for advice about treatment options and we are delighted that Neuromod’s commitment to building compelling evidence is reflected in this new rating for Lenire.”

Lenire’s Tinnitus UK Reputation Built on Years of Research

Lenire is a bimodal neuromodulation device which has been proven to provide long lasting relief from tinnitus, according to the company. Lenire treats tinnitus through a combination of auditory and tongue stimulation that retrains the brain to significantly reduce tinnitus focus.

Neuromod has conducted research to evaluate the device’s safety and effectiveness with real world patients and across three large-scale clinical trials featuring more than 600 patients.

“Tinnitus UK’s vision is for a world without tinnitus, so new, rigorous research is welcomed with open arms. This change to the charity’s assessment of Lenire recognizes years of hard work, building an evidence base that stands up to serious scrutiny,” says Tinnitus UK CEO Alex Brooks-Johnson. “We hope it encourages other researchers and companies to do the same—to take tinnitus seriously, and give people living with tinnitus the treatment options that they need and deserve.”

Lenire is Available Across the UK, US, and Europe

Lenire is exclusively available through hearing healthcare professionals across the United Kingdom, Europe, and the United States. Tinnitus patients who wish to be assessed for Lenire can find a specialized clinic at www.lenire.com/find-a-clinic/.